Anavex life sciences initiates placebo-controlled u.s. phase 2 clinical trial of anavex®3-71 in schizophrenia

First patient screened ahead of schedule trial to investigate positive, negative, and cognitive domains of schizophrenia anavex®3-71's differentiated dual novel mechanism of action offers the potential to synergistically activate both sigmar1 and m1 muscarinic receptors and treat all symptom domains of schizophrenia without the side effects of standard of care antipsychotics new york, march 18, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including alzheimer's disease, parkinson's disease, rett syndrome, schizophrenia, and other central nervous system (cns) diseases, today announced that the first patient in its u.s. fda cleared placebo-controlled phase 2 clinical study of anavex®3-71 for the treatment of schizophrenia has been screened ahead of schedule. “initiating our phase 2 trial of anavex®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated christopher u missling, phd, president and chief executive officer of anavex.
AVXL Ratings Summary
AVXL Quant Ranking